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expression was determined upon treatment of OA chondrocytes
with cytokines and growth factors.
Results: IGFBP-5 was expressed in human chondrocytes with
levels signiﬁcantly (p<0.04) lower in OA. Computational algo-
rithms identiﬁed miR-140 and miR-27a as possible regulators of
MMP-13 and IGFBP-5 expression. Data showed that both miR-
NAs were expressed in chondrocytes. There was a signiﬁcant
(p<0.01) reduction in miR-140 expression in OA, whereas miR-
27a expression was only slightly decreased. Transfection with pre-
miR-140 signiﬁcantly (p<0.005) decreased IGFBP-5 expression
at 24 hours, while pre-miR-27a did not affect either MMP-13 or
IGFBP-5. Treatment with anti-miR-27a, but not with anti-miR-140,
signiﬁcantly increased the expression of both MMP-13 (p<0.05)
and IGFBP-5 (p<0.01) after 72 hours incubation. These data
indicate that IGFBP-5 is a direct target of miR-140, whereas miR-
27a indirectly down-regulates both MMP-13 and IGFBP-5. TGF-β
down-regulates miR-140 and up-regulates IGFBP-5.
Conclusions: This study is the ﬁrst to show the involvement of
miRNAs in human OA chondrocytes. Their effect on two genes
involved in OA pathophysiology adds another level of complexity
to gene regulation, which could open up novel avenues in OA
therapeutic strategy
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Purpose: To identify genes showing altered expression in os-
teoarthritic cartilage and synovium. Dkk3, a member of the Dick-
oppf family of Wnt signalling antagonsists was overexpressed and
this work highlights the potential function of Dkk3 in OA.
Methods: Real-time PCR was used to compare expression of 270
cytokines, chemokines and their receptors in cartilage and syn-
ovium from OA and non-OA patients. Expression of Dkk3 during
chondrogenic differentiation of ATDC5 cells was also assessed
using real-time PCR and compared to ATDC5 cells not stimu-
lated to undergo chondrogenesis. The effect of TGFb on Dkk3
expression in chondrocytes was measured following treatment of
SW1353 cells with TGFb. To assess the distribution of Dkk3 in OA
cartilage immunohistochemistry was carried out on anteromedial
gonarthrosis specimens. The level of Dkk3 in synovial ﬂuid tricom-
partmental and unicompartmental cartilage lesions was measured
using ELISA.
Results: Several components of the Wnt pathway showed altered
expression between normal and OA tissue. Strikingly, the greatest
and most signiﬁcant change was in Dkk3 expression, with a 10-fold
increase in OA cartilage (p=0.00011) and a 3.5-fold increase in OA
synovium (p=0.007) when compared to respective control tissues.
Dkk3 expression decreased during chondrogenic differentiation of
ATDC5 cells and to be decreased following TGFβ treatment of
SW1353 cells.
Immunohistochemical analysis of specimens from individuals with
anteromedial gonarthrosis (AMG, a subtype of knee OA), demon-
strated Dkk3 protein in chondrocytes of the superﬁcial zones of
the cartilage, but not the deeper zones. Additionally there is an
increase in Dkk3 expression in superﬁcial zone chondrocytes in
damaged when compared to undamaged cartilage from within the
same knee. Using ELISA we have shown increased Dkk3 pro-
tein in the synovial ﬂuid of individuals with tricompartmental OA
(n=4) versus those with unicompartmental cartilage lesions (n=10)
(182ng/ml v 116 ng/ml, p<0.01, a single non-OA control synovial
ﬂuid measured 43ng/ml.
Conclusions: Dkk3 is a molecule with poorly ascribed function,
especially within the musculoskeletal system. In contrast to other
members of the Dkk family, Dkk3 does not act consistently as a
Wnt antagonist. Literature on a number of tumour-derived cells
shows that Dkk3 can potentially regulate Wnt, TGFβ, BMP, FGF
and Activin signalling and cell proliferation and apoptosis. These
cellular processes are highly relevant to OA. In this preliminary
study we have shown that Dkk3 is overexpressed in OA cartilage
and synovium. Interestingly, the increased expression of Dkk3 is
also detected at the protein level in the synovial ﬂuid; with in-
creased Dkk3 present as disease severity increases. Furthermore
Dkk3 protein in cartilage is detected more highly in damaged artic-
ular cartilage when compared to macroscopically normal cartilage.
The decreased expression of Dkk3 during chondrogenesis is sug-
gestive of a role of Dkk3 not only in articular cartilage maintenance
but also in development. We have also seen decreased expres-
sion of Dkk3 in response to TGFβ treatment. Our current work
aims to identify the function of Dkk3 in articular chondrocytes,
the signaling pathways activated by Dkk3 and the mechanisms
causing increased Dkk3 expression in OA.
Dkk3 is an intriguing molecule in the Wnt signalling ﬁeld since the
evidence for its function as a Wnt antagonist is at best equivocal.
Evidence for a role for Dkk3 in OA is compelling. Dissecting its
function in cartilage and OA will both shed light on its overall
molecular mechanism of action, enhance our knowledge of the
pathogenesis of OA and also uncover potential new therapeutic
targets for chondroprotection.
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Purpose: Traumatic joint injury in humans, irrespective of im-
mediate surgical intervention, increases the risk for osteoarthritis
(OA) development in later years. OA involves articular cartilage
degradation, characterized by release of aggrecan and collagen
fragments, and subsequent loss of tissue integrity and mechanical
properties. The evolution of this disease state from joint injury is
not clearly understood. Aggrecanases play a major role in cartilage
degradation, and ARGS-aggrecan generated by direct cleavage
of aggrecan core protein by aggrecanases is the most abundant
aggrecan fragment in OA synovial ﬂuid (SF). The current study
measures the level of aggrecanase generated ARGS-aggrecan
fragments in the SF of humans with joint injuries in comparison
to OA patients, and in preclinical animal models of joint injury, in
order to understand the evolution of disease from injury and to
facilitate pharmacologic intervention.
Methods: The ARGS-aggrecan ELISA used anti-aggrecan ab,
AHP0022 (Invitrogen) for capture, and BC-3 (Abcam) for detec-
tion. Aggrecan puriﬁed from human cartilage and cleaved with
ADAMTS4 served as standard, the range of detection was 10-500
ng aggrecan. SF from patients with anterior cruciate ligament rup-
ture (ACL, 53), meniscus injury (69), OA (11), and knee-healthy
reference subjects (8) from Lund University, Sweden were tested
for ARGS-aggrecan at appropriate dilutions. Joint instability was
induced in rats by medial meniscal surgery. SF lavage samples
were collected at 4 days, and at 1, 2, 3, 5 and 8 weeks post
surgery. ARGS-aggrecan levels were determined with contralat-
eral knees as controls.
Results: ARGS-aggrecan concentrations ranged from 2-590
μg/ml in human SF samples. ACL, meniscus injury and OA SF
